Product Description: Triclabendazole is an orally active parasite inhibitor. Triclabendazole has anti-Leishmania activity and induces gasdermin E (GSDME)-dependent pyroptosis by caspase-3 activation. Triclabendazole can be used for the research of fasciola hepatica[1][2][3].
Applications: COVID-19-anti-virus
Formula: C14H9Cl3N2OS
References: [1]Yan L, et al. Triclabendazole induces pyroptosis by activating caspase-3 to cleave GSDME in breast cancer cells [J]. Frontiers in Pharmacology, 2021, 12: 670081./[2]Devine C, et al. Potentiation of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica following its co-administration with the metabolic inhibitor, ketoconazole [J]. Veterinary parasitology, 2012, 184(1): 37-47./[3]Borges B S, et al. In vitro anti-Leishmania activity of triclabendazole and its synergic effect with amphotericin B [J]. Frontiers in Cellular and Infection Microbiology, 2023, 12: 1044665.
CAS Number: 68786-66-3
Molecular Weight: 359.66
Compound Purity: 98.72
Research Area: Infection
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Bcl-2 Family;Caspase;Parasite;PARP;Pyroptosis
English
Deutsch
